Compendium of Cancer Genome Aberrations

HAEM5:Volunteer Assignments and Opportunities: Difference between revisions

← Older edit
VisualWikitext
Sumire.Kitahara (talk | contribs)
editor
212 edits
No edit summary
No edit summary
 
(39 intermediate revisions by 4 users not shown)
Line 509: Line 509:
|[[HAEM5:Acute myeloid leukaemia with other defined genetic alterations|Acute myeloid leukaemia with other defined genetic alterations]]
|[[HAEM5:Acute myeloid leukaemia with other defined genetic alterations|Acute myeloid leukaemia with other defined genetic alterations]]
|Disease
|Disease
|Samreen Mehak (trainee), Malini Sathanoori
|3/2/2026
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 839: Line 839:
|[[HAEM5:Myeloid/lymphoid neoplasm with FLT3 rearrangement|Myeloid/lymphoid neoplasm with FLT3 rearrangement]]
|[[HAEM5:Myeloid/lymphoid neoplasm with FLT3 rearrangement|Myeloid/lymphoid neoplasm with FLT3 rearrangement]]
|Disease
|Disease
|Riku Das, PhD
|2/19/2026
|5/20/2026
|Pending
|
|
|
|Normally FQR, but Katie Schieffer instead
|
|
|
|FQR
|
|
|
|
Line 1,403: Line 1,403:
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]]
|Disease
|Disease
|Karin Miller, MD
|To be covered in B-ALL, NOS
|10/9/2025
|
|
|
|
|
Line 1,422: Line 1,422:
|
|
|
|
|
|'''Complete'''
|
|11/21/2025
|SK
|SK
|
|2/14/2026
|
|
|B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy
|B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy
Line 1,438: Line 1,438:
|
|
|
|
|
|'''Complete'''
|
|11/21/2025
|SK
|SK
|
|2/14/2026
|
|
|B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy
|B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy
Line 1,452: Line 1,452:
|Disease
|Disease
|Holli Drendel, PhD
|Holli Drendel, PhD
|Nov 11/2025
|
|
|
|Pending
|?Complete? Looks like tables need more editing.
|
|
|SK
|SK
Line 1,469: Line 1,469:
|Karin Miller, MD
|Karin Miller, MD
|10/9/2025
|10/9/2025
|
|12/5/2025
|
|
|
|
Line 1,483: Line 1,483:
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]]
|Disease
|Disease
|Mark G. Evans, MD; Kilannin Krysiak, PhD
|Mark G. Evans, MD
|10/1/2025
|10/1/2025
|11/17/2025
|11/17/2025
|Pending
|'''Complete'''
|
|11/8/2025
|SK
|SK
|
|2/14/2026
|
|
|B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like
|B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like
Line 1,583: Line 1,583:
|10/10/2025
|10/10/2025
|11/24/2025
|11/24/2025
|Pending
|'''Complete but needs a few edits'''
|
|11/11/2025
|SK
|SK
|
|2/14/2026
|
|
|NEW (No Prior)
|NEW (No Prior)
Line 1,598: Line 1,598:
|Lei Zhang, PhD
|Lei Zhang, PhD
|10/10/2025
|10/10/2025
|
|12/22/2025
|Pending
|Pending
|
|
Line 1,611: Line 1,611:
|-
|-
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma, NOS|B-lymphoblastic leukaemia/lymphoma, NOS]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma, NOS|B-lymphoblastic leukaemia/lymphoma, NOS]]
|Disease (See [https://ccga.io/index.php/HAEM5:B-lymphoblastic_leukaemia/lymphoma B-lymphoblastic leukaemia/lymphoma])
|Disease  
|
|Karin Miller, MD
----
|10/9/2025
|11/24/2025
|Pending
|
|
----
|SK
|
----
|
----
|
----
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|-
|-
!Disease (5th Edition)
!Disease (5th Edition)
Line 1,743: Line 1,730:
|
|
|-
|-
|[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease||
|[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease||Sriharikrishnaa S
| || || || ||SG|| ||Need new author to update latest content. Prior author cannot update the page.
| 4/10/2026|| || Pending|| ||SG|| ||Need new author to update latest content. Prior author cannot update the page.
|Splenic Diffuse Red Pulp Small B-cell Lymphoma
|Splenic Diffuse Red Pulp Small B-cell Lymphoma
|Snehal Patel, MD, PhD
|Snehal Patel, MD, PhD
Line 1,753: Line 1,740:
|[[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli|Splenic B-cell lymphoma/leukaemia with prominent nucleoli]]
|[[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli|Splenic B-cell lymphoma/leukaemia with prominent nucleoli]]
|Disease
|Disease
|Pallavi Khattar
|3/2/2026
|
|
|
|PENDING
|
|
|
|
|SG
|SG
Line 1,769: Line 1,756:
|[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]]
|[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]]
|Disease
|Disease
|Pallavi Khattar
|3/2/2026
|
|
|
|PENDING
|Sent e-mail to prev authors no reply
|
|
|
|SG
|SG
|
|
|Email sent to request to update 2024
|Email sent to request to update 2024. Sent e-mail to prev authors no reply.
|(1) Lymphoplasmacytic Lymphoma + (2) Waldenstrom Macroglobulinemia
|(1) Lymphoplasmacytic Lymphoma + (2) Waldenstrom Macroglobulinemia
|(1 and 2) Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD  Departments of Pathology, Laboratory Medicine, and Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI)
|(1 and 2) Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD  Departments of Pathology, Laboratory Medicine, and Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI)
Line 1,785: Line 1,772:
|[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]]
|[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]]
|Disease
|Disease
|Pallavi Khattar
|3/2/2026
|
|
|
|PENDING
|Sent e-mail to prev authors no reply
|
|
|
|SG
|SG
|
|
|Email sent to request to update 2024
|Email sent to request to update 2024. Sent e-mail to prev authors no reply
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)
|Whayoung Lee, MD (trainee), Fabiola Quintero-Rivera, MD, FACMG*
|Whayoung Lee, MD (trainee), Fabiola Quintero-Rivera, MD, FACMG*
Line 1,947: Line 1,934:
|[[HAEM5:In situ mantle cell neoplasm|In situ mantle cell neoplasm]]
|[[HAEM5:In situ mantle cell neoplasm|In situ mantle cell neoplasm]]
|Disease
|Disease
|Sriharikrishnaa S
|4/10/2026
|
|
|
|Pending
|
|
|
|
|SG
|SG
Line 2,448: Line 2,435:
====CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)====
====CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)====
|-
|-
|[[HAEM5:Kikuchi-Fujimoto disease|Kikuchi-Fujimoto disease]]||Disease|| || || || || ||Sumi Kitahara (SK)
|[[HAEM5:Kikuchi-Fujimoto disease|Kikuchi-Fujimoto disease]]||Disease|| Sumire Kitahara, MD|| || || '''Complete'''|| 11/6/2025||Sumi Kitahara (SK)
| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
Line 2,456: Line 2,443:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Autoimmune lymphoproliferative syndrome|Autoimmune lymphoproliferative syndrome]]||Disease||Aviv Oren, MD (trainee);
|[[HAEM5:Autoimmune lymphoproliferative syndrome|Autoimmune lymphoproliferative syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]]
Karin Miller, MD
|
|3/25/2024
| ||
| || || ||SK|| ||
| || || ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,485: Line 2,472:
|
|
|
|
|Pending
|
|
|
|SK
|SK
Line 2,498: Line 2,485:
|[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]]
|[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]]
|Disease
|Disease
|Parastou Tizro, MD (trainee);
|Parastou Tizro, MD;
Celeste Eno, PhD
Celeste Eno, PhD; Sumire Kitahara, MD
|3/17/2024
|9/23/2025
|
|11/4/2025
|Complete
|'''Complete'''
|6/24/2024
|11/4/2025
|SK
|SK
|7/1/2024
|11/6/2025
|
|
|NEW (No Prior)
|NEW (No Prior)
Line 2,529: Line 2,516:
|9/24/2025
|9/24/2025
|12/9/2025
|12/9/2025
|Pending
|'''Complete'''
| ||SK|| ||
| 12/17/2025||SK|| 1/6/2026||
|Chronic Lymphoproliferative Disorder of NK Cells
|Chronic Lymphoproliferative Disorder of NK Cells
|Michelle Don, MD
|Michelle Don, MD
Line 2,550: Line 2,537:
|[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||Daynna J. Wolff, PhD
|[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||Daynna J. Wolff, PhD
|3/22/2024
|3/22/2024
| || || ||SK|| ||
|follow-up needed
| || ||SK|| ||
|Sézary Syndrome
|Sézary Syndrome
|Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina
|Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina
Line 2,557: Line 2,545:
|
|
|-
|-
|[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease||Rabail Aslam, MD (fellow);
|[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease||Shashirekha Shetty, PhD
Shashirekha Shetty, PhD
|10/15/2025||1/19/2026
|7/1/2024||8/31/2024
|Pending
|Pending
| ||SK|| ||
| ||SK|| ||
Line 2,584: Line 2,571:
!Prior Notes (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Amanda Xu, MD/MSc; Teodora Popa (resident)
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Abdelrahman Dabash
|3/19/2024
(trainee) and Ian King, PhD
| ||Pending
|1/6/2026
| 2/3/2026||
| ||SK|| ||
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
Line 2,598: Line 2,586:
Andrew Siref, MD
Andrew Siref, MD
|10/14/2025
|10/14/2025
| ||Pending
|11/24/2025
| ||SK|| ||
|'''Complete'''
| 12/29/2025||SK|| 1/6/2026||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,608: Line 2,597:
|[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||Daynna J. Wolff, PhD
|[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||Daynna J. Wolff, PhD
|3/22/2024
|3/22/2024
| || || ||SK|| ||
|follow-up needed|| || ||SK|| ||
|Mycosis Fungoides
|Mycosis Fungoides
|Jane Scribner, MD and Daynna J. Wolff, PhD
|Jane Scribner, MD and Daynna J. Wolff, PhD
Line 2,618: Line 2,607:
Shashirekha Shetty, PhD
Shashirekha Shetty, PhD
|7/1/2024
|7/1/2024
|8/31/224
|follow-up needed
|Pending
|
| ||SK|| ||
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
Line 2,629: Line 2,618:
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||Rabail Aslam, MD (fellow);
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||Rabail Aslam, MD (fellow);
Shashirekha Shetty, PhD
Shashirekha Shetty, PhD
|7/1/2024||8/31/2024
|7/1/2024||follow-up needed
|Pending
|
| ||SK|| ||
| ||SK|| ||
|Primary Cutaneous Anaplastic Large Cell Lymphoma
|Primary Cutaneous Anaplastic Large Cell Lymphoma
Line 2,638: Line 2,627:
|
|
|-
|-
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Raniah Alamri (Hemepath trainee)
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Ian King, PhD
|3/19/2024
Katelyn Swanson, DO (trainee)
| ||Pending
|11/19/2025
| ||SK|| ||
|12/19/2025
|'''Complete'''
| 1/6/2026||SK|| 1/6/2026||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,651: Line 2,642:
Sumire Kitahara, MD
Sumire Kitahara, MD
|6/30/2024
|6/30/2024
| ||Pending
|11/9/2025
|Pending
| ||SK|| ||
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
Line 2,662: Line 2,654:


Andrew Siref, MD
Andrew Siref, MD
|10/14/2025|| ||Pending
|10/14/2025||11/24/2025
| ||SK|| ||
|'''Complete'''
| 12/29/2025||SK|| 1/6/2026||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,740: Line 2,733:
|9/24/2025
|9/24/2025
|11/9/2025
|11/9/2025
|Pending
|'''Complete'''
|Old template completed 5/13/24||SK||10/18/24||
|12/17/2025
|SK||1/6/2026||
|Hepatosplenic T-cell Lymphoma
|Hepatosplenic T-cell Lymphoma
|Michelle Don, MD, MS
|Michelle Don, MD, MS
Line 2,751: Line 2,745:


Sumire Kitahara, MD
Sumire Kitahara, MD
|6/6/24|| ||Pending
|6/6/24|| ||
| ||SK|| ||
| ||SK|| ||
|Anaplastic Large Cell Lymphoma, ALK-Positive
|Anaplastic Large Cell Lymphoma, ALK-Positive
Line 2,765: Line 2,759:
|[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee);
|[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee);
Sumire Kitahara, MD
Sumire Kitahara, MD
|6/6/24|| ||Pending
|6/6/24|| ||
| ||SK|| ||
| ||SK|| ||
|Anaplastic Large Cell Lymphoma, ALK-Negative
|Anaplastic Large Cell Lymphoma, ALK-Negative
Line 2,799: Line 2,793:
!Prior Notes (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Hayk Simonyan (trainee) and Ian King||3/16/2026
| ||Pending|| ||SK|| ||prior authors not available
|
| || ||SK|| ||prior authors not available; Rachel Burnside volunteered in 7/28/2023 but had to step back so found new author.
|Angioimmunoblastic T-cell Lymphoma
|Angioimmunoblastic T-cell Lymphoma
|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG
|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG
Line 2,807: Line 2,802:
|
|
|-
|-
|[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside, PhD||7/28/2023
|[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Ian King||3/16/2026
| ||Pending|| ||SK|| ||
|
| || ||SK|| ||Rachel Burnside volunteered in 7/28/2023 but had to step back so found new author.
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,815: Line 2,811:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Nodal TFH cell lymphoma, NOS|Nodal TFH cell lymphoma, NOS]]||Disease||
|[[HAEM5:Nodal TFH cell lymphoma, NOS|Nodal TFH cell lymphoma, NOS]]||Disease||Ian King
| || || || ||SK|| ||
| 3/16/2026|| || || ||SK|| ||
|Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype
|Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype
|Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD
|Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD
Line 2,824: Line 2,820:
|-
|-
|[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease||Bo Hong, MD
|[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease||Bo Hong, MD
|6/25/2023
|10/14/2025
| || || ||SK|| ||
|12/3/2025
|Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,841: Line 2,839:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Amanda Xu, MD/MSc;
|[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Maryam Mehdiopour Dalivand (trainee); Ian King, PhD
Teodora Popa (resident)
|1/6/2026
|3/19/2024
| 2/3/2026||Complete
| ||Pending
| 1/27/2026||SK|| 2/14/2026||
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,868: Line 2,865:
|[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD
|[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD
|3/25/2024
|3/25/2024
| || || ||SK|| ||
| 11/17/2025||'''Complete'''
| 11/17/2025||SK|| 2/14/2026||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,877: Line 2,875:
|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD
|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD
|3/25/2024
|3/25/2024
| || || ||SK|| ||prior authors not available
| 11/17/2025||'''Complete'''
| 11/18/2025||SK|| 2/14/2026||prior authors not available
|Systemic EBV-Positive T-cell Lymphoma of Childhood
|Systemic EBV-Positive T-cell Lymphoma of Childhood
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA
Retrieved from "https://content.ccga.io/index.php/HAEM5:Volunteer_Assignments_and_Opportunities"